Advertise on podcast: The GMP Insider

Nearly nine out of ten human-drug warning letters include at least one inadequate CAPA response. Your corrective action plan is the single most rejected document in FDA enforcement — and it's not for lack of effort. Marcus and Priya count down the five CAPA effectiveness failures that keep quality teams in warning-letter territory: fixing the event instead of the system, root causes that stop at human error, CAPAs closed with no proof they worked, CAPAs written to answer the 483 instead of fixing the system, and no trending — so the failure recurs.• Why CAPA is the most rejected document in FDA enforcement• Failure one: corrective action with no preventive action — fixing the event, not the system• Failure two: root causes that stop at "human error"• Failure three: closing a CAPA with zero evidence the change worked• Failure four: CAPAs written to answer the 483 observation, not to fix the system• Failure five: no trending — the same failure recurs, and FDA cites recurrence• The Monday-morning CAPA playbook that survives an investigatorNew episodes every Monday and Wednesday — follow The GMP Insider so you never miss one.Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161Watch on YouTube: https://www.youtube.com/@TheGMPInsiderProduced with AI assistance.

Nearly nine out of ten human-drug warning letters include at least one inadequate CAPA response. Your corrective action plan is the single most rejected document in FDA enforcement — and it's not for lack of effort. Marcus and Priya count down the five CAPA effectiveness failures that keep quality teams in warning-letter territory: fixing the event instead of the system, root causes that stop at human error, CAPAs closed with no proof they worked, CAPAs written to answer the 483 instead of fixing the system, and no trending — so the failure recurs.• Why CAPA is the most rejected document in FDA enforcement• Failure one: corrective action with no preventive action — fixing the event, not the system• Failure two: root causes that stop at "human error"• Failure three: closing a CAPA with zero evidence the change worked• Failure four: CAPAs written to answer the 483 observation, not to fix the system• Failure five: no trending — the same failure recurs, and FDA cites recurrence• The Monday-morning CAPA playbook that survives an investigatorNew episodes every Monday and Wednesday — follow The GMP Insider so you never miss one.Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161Watch on YouTube: https://www.youtube.com/@TheGMPInsiderProduced with AI assistance.

An out-of-specification result lands on your desk — and one wrong decision in the next hour can manufacture the evidence for your own warning letter. Marcus and Priya break down the two-phase OOS investigation step by step: Phase 1, the laboratory investigation, and Phase 2, the full-scale investigation, under 21 CFR 211.192 — from the Barr Labs decision to the retest rules to what to do on Monday morning.• Phase 1 vs Phase 2: what each phase covers and where the line is• The retest rules — when retesting is legitimate and when it's testing into compliance• Why "no assignable lab cause" is a finding, not a failure• What 21 CFR 211.192 actually requires, in plain language• The Monday-morning OOS playbook, in five stepsNew episodes every Monday and Wednesday — follow The GMP Insider so you never miss one.Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161Watch on YouTube: https://www.youtube.com/@TheGMPInsiderProduced with AI assistance.

When an FDA investigator stops trusting your data, the inspection is over — because if the records can't be trusted, nothing built on them can be. Marcus and Priya break down all nine ALCOA+ principles — Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, Available — what investigators actually find when each one is missing, and the Monday-morning fixes that close most findings before they happen.• The 9 ALCOA+ principles, explained in plain language• What investigators actually check first: audit trails, user access, backups, QA's real role• Why most data integrity 483s are discipline failures, not technology failures• The small-site objection steel-manned: where the money actually matters• The 4 moves a QA manager should make this weekNew episodes every Monday and Wednesday — follow The GMP Insider so you never miss one.Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161Watch on YouTube: https://www.youtube.com/@TheGMPInsiderProduced with AI assistance.

Every year, FDA investigators write thousands of 483 observations — and almost every one was avoidable. Marcus and Priya count down the ten most-cited observations in drug manufacturing for 2026, what investigators are actually finding, and exactly how to keep your site off the list.• The #1 most-cited observation — and why it explains the other nine• Data integrity: the fastest-growing citation cluster in 2026• Why "human error + retraining" keeps failing investigations• The one quality-unit decision that changes everythingNew episodes every Monday and Wednesday — follow The GMP Insider so you never miss one.Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161Watch on YouTube: https://www.youtube.com/@TheGMPInsiderProduced with AI assistance.

Every shortcut, deferred CAPA, and "we'll fix it later" is a loan — and quality debt charges interest. Repeat deviations, findings, and warning letters are just the payments coming due. • What quality debt is and how it silently accumulates • The interest payments: repeat deviations and FDA findings • Paying it down without stopping the line • Preventing new debt while clearing the old New episodes every Monday and Wednesday — follow The GMP Insider so you never miss one. Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161 Watch on YouTube: https://www.youtube.com/@TheGMPInsider Produced with AI assistance.

Recalls make the headlines. But the real cost of poor quality never makes the press release — it hides in rework, investigations, remediation, and the launches that never happen. • The costs nobody puts on the recall announcement • Rework, investigations, and remediation: the real math • How poor quality taxes every future product launch • Making the business case for quality investment New episodes every Monday and Wednesday — follow The GMP Insider so you never miss one. Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161 Watch on YouTube: https://www.youtube.com/@TheGMPInsider Produced with AI assistance.

Your CAPA system can be perfect on paper and still change nothing — because CAPAs fix symptoms, and culture is the system underneath. • Why brilliant CAPAs die in broken cultures • Symptoms vs systems: knowing which one you're treating • What culture change actually requires from QA leaders • Building a system where CAPAs stick New episodes every Monday and Wednesday — follow The GMP Insider so you never miss one. Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161 Watch on YouTube: https://www.youtube.com/@TheGMPInsider Produced with AI assistance.

Compliant doesn't mean effective. Effective doesn't mean sustainable. Most quality systems are only one of the three — and leadership can't tell which. • The three lenses every quality system needs • Why compliance alone is a fragile victory • Measuring effectiveness, not just activity • Building a system that lasts beyond the next inspection New episodes every Monday and Wednesday — follow The GMP Insider so you never miss one. Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161 Watch on YouTube: https://www.youtube.com/@TheGMPInsider Produced with AI assistance.

Every metric green, every trend flat — and the system is rotting underneath. Dashboards don't lie on purpose. They lie by design. • Why green metrics create dangerous comfort • The quality signals dashboards systematically miss • What to measure when the numbers look fine • Leading beyond the dashboard New episodes every Monday and Wednesday — follow The GMP Insider so you never miss one. Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161 Watch on YouTube: https://www.youtube.com/@TheGMPInsider Produced with AI assistance.

Saying no in QA is easy on paper and brutal in practice. This episode is about the decision nobody wants to make — and why making it is the job. • Why "no" is a quality decision, not a career risk • How great QA leaders frame rejection so it actually lands • The difference between blocking progress and protecting patients • Sleeping well after the hardest call of your career New episodes every Monday and Wednesday — follow The GMP Insider so you never miss one. Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161 Watch on YouTube: https://www.youtube.com/@TheGMPInsider Produced with AI assistance.

AI governance in the pharmaceutical industry cannot begin after deployment. By that point, critical decisions about data, accountability, human oversight, transparency, risk, and system behavior have already been embedded into the technology. So the better question is: What if ethics were designed into AI from the beginning? In this episode of The GMP Insider, we explore the concept of Ethics by Design and why it could become a foundational pillar of responsible AI governance in pharmaceutical Quality. Discussion topics include: Why AI governance must begin during system design Patient safety considerations when AI makes mistakes Transparency and understanding AI outputs Designing meaningful human oversight Data integrity and AI governance Identifying potential bias and unintended outcomes Defining accountability when AI contributes to decisions Managing AI and model changes throughout the lifecycle The evolving role of QA in AI governance Why policies alone may not be sufficient for complex AI systems For GxP and other regulated environments, responsible AI requires more than a policy describing how technology should be used. Organizations need governance principles embedded into the design, validation, deployment, monitoring, and change management lifecycle. The objective shouldn't be to create another compliance checklist. It should be to build systems with appropriate ethical guardrails from the start. Because as AI becomes more complex, governance must become more intentional. Define accountability before deployment. Design for human oversight. Protect data integrity. Monitor continuously. Engineer trust from the beginning. The central question for pharmaceutical AI should not simply be: "Can we use this technology?" It should also be: "Can we govern it responsibly—and can we trust the way it was designed?" You cannot govern complexity effectively if ethics is treated as an afterthought. From batch to patient — quality is everything.

What is it really like to work in Quality Assurance at a large pharmaceutical company compared with a smaller organization? The answer goes far beyond company size. In this episode of The GMP Insider, we explore how Big Pharma and Small Pharma can develop very different professional skills, experiences, and perspectives—and why Quality Culture often matters more than organizational scale. Big Pharma can provide mature systems, specialized expertise, global standards, established governance, and the opportunity to learn how to operate within complex organizations. Small Pharma can provide broader responsibilities, faster decision-making, greater visibility, cross-functional exposure, and opportunities to build Quality Systems from the ground up. Neither is inherently better. They simply develop different muscles. In this episode, we discuss: The advantages of working in Big Pharma The professional opportunities available in Small Pharma Managing complexity versus creating change How organizational size affects decision-making The importance of leadership and Quality Culture Why speaking up and challenging respectfully matter How both environments can accelerate a QA professional's career What truly defines an exceptional Quality organization The best Quality culture isn't necessarily found in the company with the largest budget or the most sophisticated systems. It's found where people are empowered to speak up, learn from failures, take ownership, support each other, and put patients first. Big Pharma can teach you how to manage complexity. Small Pharma can teach you how to create change. The strongest professionals learn from both. Company size may shape the system. Leadership and culture shape the experience. From batch to patient — quality is everything.

What if the deepest meaning of Pharmaceutical Quality isn't compliance? What if it's caring? Every SOP written, every deviation investigated, every batch reviewed, and every quality decision made represents something bigger than a regulatory requirement. It represents a person who cared enough to do the work right. In this episode of The GMP Insider, we explore the human side of pharmaceutical quality and the purpose behind the systems, procedures, investigations, and decisions that protect patients every day. Discussion Topics Why Quality is more than compliance The human purpose behind SOPs and Quality Systems Why investigations matter beyond simply closing deviations How batch review connects directly to patient safety Why challenging a decision can be an act of caring The invisible people behind every medicine How purpose can transform routine quality activities into meaningful work Patients may never know the names of the people who wrote the procedures, investigated the deviations, reviewed the data, or released their medicine. They may never see the countless decisions made behind the scenes. But they experience the result. That is the quiet beauty of Pharmaceutical Quality. Someone cared enough to protect a stranger. Quality is caring expressed through action. And perhaps that's why the work we do matters so much. Quality happens behind the scenes. Its impact is felt by every patient. From batch to patient — quality is everything

Some of the hardest decisions in Pharmaceutical Quality are not difficult because the answer is unclear. They're difficult because the right answer isn't necessarily the popular one. A Quality Leader may have to say no. They may have to escalate an uncomfortable issue. They may have to challenge production pressure. They may have to make a decision that creates short-term frustration but protects long-term patient safety. In this episode of The GMP Insider, we explore why great QA Leaders choose integrity over popularity and how difficult decisions shape trust, credibility, and Quality Culture. Discussion Topics Why integrity is fundamental to Quality Leadership Making difficult decisions under operational pressure Choosing patient safety over popularity Building trust through consistent decision-making The difference between authority and leadership Why the best leaders make decisions they can defend How difficult decisions create lasting leadership credibility The strongest QA Leaders don't measure success by how many people agree with them. They measure it by whether they made the right decision for the right reasons. Because sometimes leadership means standing alone. Sometimes it means saying no. And sometimes it means making the decision that nobody wants today—but everyone will be grateful for tomorrow. Popularity is temporary. Integrity builds a legacy. And when a Quality Leader knows they protected the patient, they can sleep well after even the most difficult decision. From batch to patient — quality is everything